Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer

International Journal of Cancer

Volumn 124, Issue 10, 2009, Pages 2353-2360

  Zeimet, Alain G ^a   Reimer, Daniel ^a   Wolf, Dominik ^a   Fiegl, Heidi ^a   Concin, Nicole ^a   Wiedemair, Annemarie ^a   Wolf, Anna M ^a   Rumpold, Holger ^a   Müller Holzner, Elisabeth ^a   Marth, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cancer immunology; Interferon regulatory factors; Ovarian cancer; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; PRIMER DNA;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MESOTHELIUM CELL; OUTCOME ASSESSMENT; OVARY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; UPREGULATION; AGED; DRUG EFFECT; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR CELL LINE;

AGED; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTOR-2; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 64249139284     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24214     Document Type: Article

References (24)

1. IARC: GLOBOCAN. Cancer incidence, mortality and prevalence worldwide, 2002. Available at http://www-dep.iarc.fr/.
2. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
3. Curiel TJ, Coukos G, Zou L, Avarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burrow M, Zhu Y, Wei S, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
4. Marth C, Fiegl H, Zeimet AG, Müller-Holzner E, Deibl M, Doppler W, Daxenbichler G. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 2004; 191:1598-605.
5. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, François E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996;14:343-50.
6. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000;82:1138-44.
7. Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol 2008;109: 174-81.
8. Tanaka N, Taniguchi T. The interferon regulatory factors and oncogenesis. Semin Cancer Biol 2000;10:73-81.
9. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001;19:623-55.
10. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M, Taniguchi T. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993;259:971-4.
11. Lowney JK, Boucher LD, Swanson PE, Doherty GM. Interferon regulatory factor-1 and -2 expression in human melanoma specimens. Ann Surg Oncol 1999;6:604-8.
12. Connett JM, Badri L, Giordano TJ, Connett WC, Doherty GM. Interferon regulatory factor 1 (IRF-1) and IRF-2 expression in breast cancer tissue microarrays. J Interferon Cytokine Res 2005;25:587-94.
13. Kim EJ, Lee JM, Namkoong SE, Um SJ, Park JS. Interferon regulatory factor-1 mediates interferon-gamma-induced apoptosis in ovarian carcinoma cells. J Cell Biochem 2002;85:369-80.
14. Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, Stadlmann S, Daxenbichler G, Dapunt O. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol 1996;62:384-9.
15. Siemens CH, Auersperg N. Serial propagation of human ovarian surface epithelium in tissue culture. J Cell Physiol 1988;134:347-56.
16. Wang Y, Liu DP, Chen PP, Koeffler HP, Tong XJ, Xie D. Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res 2007;67:2535-49.
17. Vaughan PS, van der Meijden CMV, Aziz F, Harada H, Taniguchi T, van Wijnen AJ, Stein JL, Stein GS. Cell cycle regulation of histone H4 gene transcription requires the oncogenic factor IRF-2. J Biol Chem 1998;273:194-9.
18. Yoshino A, Katayama Y, Yokoyama T, Watanabe T, Ogino A, Ota T, Komine C, Fukushima T, Kusama K. Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA. J Neurooncol 2005;74:249-60.
19. Doherty GM, Boucher L, Sorenson K, Lowney J. Interferon regulatory factor expression in human breast cancer. Ann Surg 2001; 233:623-9.
20. Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004;190:910-25.
21. Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Müller-Holzner E, Daxenbichler G, Offner FA, Dapunt O, Marth C. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 1998;16:1861-8.
22. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11:8326-31.
23. Mori K, Stone S, Khaodhiar L, Braverman LE, DeVito WJ. Induction of transcription factor interferon regulatory factor-1 by interferon-gamma (IFN gamma) and tumor necrosis factor-alpha (TNF alpha) in FRTL-5 cells. J Cell Biochem 1999;74:211-9.
24. Geller DA, Nguyen D, Shapiro RA, Nussler A, Di Silvio M, Freeswick P, Wang SC, Tweardy DJ, Simmons RL, Billiar TR. Cytokine induction of interferon regulatory factor-1 in hepatocytes. Surgery 1993;114:235-42.